Ignite Creation Date:
2024-05-05 @ 9:37 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00926289
Status:
COMPLETED
Last Update Posted:
2014-06-27
First Post:
2009-06-22
Brief Title:
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomised Double-blind Double Dummy Active Controlled Parallel Group Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg T80HCTZ25 Versus Telmisartan 80mg T80 Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension Systolic Blood Pressure SBP 160 mmHg and Diastolic Blood Pressure DBP 100 mmHg
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood PressureSBP compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension SBP160 mmHg and Diastolic Blood PressureDBP100 mmHg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-007711-32 | EUDRACT_NUMBER | EudraCT | None |